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CHAPTER 1 INTRODUCTION
1.1 Summary
1.1.1 Role of Proteins in Cancer Progression
For researchers’, cancer is one of the most complex and intriguing field of study. Since
3000 BC, scientists have been revealing many properties of cancer cells that differ from normal
cells. Cancer cells progress through an array of complex pathways and its survival depends on
how effectively it surpasses many signaling pathways. As can be seen from the famous image by
Douglas Hanahan and Weinberg, The Hallmarks of Cancer(Fig.1), cancer cells promote tumor
growth by resisting cell death and promoting angiogenesis (1). The image also signifies that all
cancer cells share six common traits or hallmarks that lead to the transformation of normal cells
to cancer cells. They are also efficient at suppression of apoptosis and sustaining proliferative
signals such as activation of (Epidermal Growth Factor Receptor) EGFR mediated Ras-Raf
pathways (2,3,4). Proteins such as these play a key role in survival of cancer cells. Studies are also
revealing many other proteins that interact with EGF and Ras for cancer cell invasion and
metastasis. Phosphorylation and de-phosphorylation of several signaling proteins play a key role
in sustaining cancer cell activity. The proteins kinases, RAF, MEK and MAPK has an active role in
controlling cell growth through phosphorylation. However, dysfunction of these kinases leads to
uncontrolled growth which is a necessary step for the development of all cancer (5).
Overexpression and dysregulation of certain proteins in normal cells triggers pathway leading to
cancer progression and invasion. One such protein that is expressed highly in many different
forms of cancer is FAM129B (6,7).
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Fig 1.1. Douglas Hanahan, Robert A. Weinberg. Hallmarks of Cancer (Cell. 2000). The author
describes the six major capabilities acquired by cells to transform to a human tumor. These six
characteristics of cancer cells are common in all forms of cancer.

1.2 Significance of Protein Phosphorylation and Dephosphorylation
Once a gene is expressed and translated into a functional cellular protein, the cell is able to
control the protein’s fate through the use of posttranslational modification (PTMs).
Phosphorylation is the most important and most thoroughly researched form of PTM. Although,
proteins undergo posttranslation modification in various form such as acylation,
carboxymethylation, tyrosine sulfation and glycosylation, none of these mechanisms is nearly as
widespread and readily subjected to regulation by physiological stimuli as is phosphorylation.
Phosphorylation occurs by covalent binding of phosphate group to certain amino acid residue
(Serine, Threonine and Tyrosine) (8). This reaction is catalyzed by protein kinase. The reverse
reaction of phosphorylation is dephosphorylation which is catalyzed by protein phosphatases (9).
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Protein kinases and phosphatases work independently and in a balance to regulate the function
of proteins (10). These two events are important switches that regulate many intracellular
functions.

Many

pathways

are

connected

through

protein

phosphorylation

and

dephosphorylation.
The dynamic process of phosphorylation plays key roles in the regulation of normal cells and
cancer cells. When the balance of phosphorylation and dephosphorylation is disturbed, cellular
activities are dysregulated leading to numerous biological problems including cancer (11). The
abnormal activation of phosphorylation through kinases have been shown to drive many
hallmarks of cancer biology including proliferation, cell survival, motility, angiogenesis,
metabolism and evasion of antitumor immune response (12). Thus, loss of negative regulation
through phosphatase activity and overexpression of kinases together play a major role in
transformation of normal cell to a cancerous one.
1.3 FAM129B
FAM129B is a protein that is expressed highly in cancer cell as compared to normal cells.
It is also known with different names like Meg-3, Minerva (Melanoma invasion by ERK) etc.
FAM129B is upregulated in many forms of cancers including breast, kidney, large intestine, lung,
endometrial cancers and hematopoietic and central nervous system tumors. It is also reported
that FAM129B localizes to plasma membrane in confluent cancer cells where it is thought to
interacts with adherens junction protein. In exponentially growing cells, it is exclusively in
cytoplasm (17). FAM129B also plays a key role in suppression of apoptosis, thus suggesting its
role in promoting cancer.
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1.4 Structure of FAM129B
The protein coding gene FAM129B is a class of family with sequence similarity 129member B. FAM129B is 746 amino acids long and approximately 84 KDa polypeptide which
belongs to a protein family of unknown category and unknown basic function. Other family
members are Niban (FAM129A), a stress-inducible gene found to be upregulated in renal and
thyroid cancer models, and novel B-cell protein 1 (BCNP1, FAM129C), a surface membrane
protein overexpressed in chronic lymphocytic leukemia (13). FAM129B and Niban/ FAM129A
share 40% sequence identity, both containing a pleckstrin homology (PH) domain, while
FAM129B shares 27% sequence identity with BCNP1/FAM129C. However, little else is known
about the function or regulation of these proteins in any organism.
Homo sapiens FAM129B consists of a conserved Pleckstrin Homology (PH)-like domain at
the N-terminal and proline rich sequence near the carboxyl end that includes a KEAP1 binding
ETGE motif at the C-terminal (Fig.2). One of the main function of PH-like domain is to bind
phosphatidylinositol lipids within biological membranes (14). These interactions help them
recruit certain proteins to the membrane thus targeting them for other cellular functions. The
isomer FAM129C also has the PH domain at the amino terminal, whereas FAM129A has only a
truncated PH domain. A conserved ETGE motif in FAM129B was found to interact with KEAP1
(15). It is thought that the interaction of FAM129B with KEAP1 plays an important role in cancer
cell proliferation by sequestering KEAP1 which in turn activates Nrf2 (responds to oxidative
stress) and IKKβ (triggers immune response) activities. The proline rich region near ETGE motif
has six serine phosphorylation sites that were first identified by a large scale phopshoproteomics
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studies. All the six sites showed direct phosphorylation by ERKs (16). The six serine
phosphorylation sites play an important role in FAM129B membrane localization.

Fig 1.2. FAM129B domain structure showing PH-like domain at N-terminal and ETGF motif at Cterminal. The six serine phosphorylation sites are P1 – P6. P1P2 and P5P6 are very close to
each other. The sites P1, P2 and P5, P6 are phosphorylated by MAP Kinase. However, the sites

P3 and P4 are far apart and not as strongly phosphorylated as the other four sites

1.5 Functions of FAM129B
The significance of this protein was first mentioned by Old and colleagues through
phosphoproteomic studies to selectively identify phosphopeptides (16). They found BRaf/MKK/ERK signaling as the effective targets of FAM129B thus implicating its role in cancer
cells. Their study found six serine phosphorylation site at the C-terminal of FAM129B and
mutation of these sites affects the way FAM129B translocate to membrane in confluent cells.
Studies have also shown that FAM129B translocate to cell membrane in confluent HeLa cells (17).
However, when cells are not in contact with each other and the adherent junction is
disassembled, FAM129B is mostly distributed in cytoplasm (Fig 1.3). The interaction of FAM129B
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with the cell membrane and its colocalization with β-catenin, a marker for cadherin-dependent
cell-cell interactions suggest that FAM129B play a key role in cancer cell invasion (17).

Fig 1.3 Endogenous FAM129B localization in confluent HeLa cells (Chen, Guy and Evans 2010).
(A). When cells are not in contact with each other and the membrane junction is not formed,
FAM129B is mostly dispersed in cytoplasm. The image shows the cytoplasmic FAM129B (red) in
exponential cells.
(B). FAM129B localizes to cell-cell adhesion junction in confluent HeLa cells. The image shows
localization of FAM129B (red) to the membrane in confluent HeLa cells.
(C). FAM129B (red) in exponentially growing HeLa culture showing some mitotic cells.

FAM129B is a novel regulator of Wnt/β-catenin signal transduction in melanoma cells
(18). Wnt signaling pathway are a group of signal transduction pathways made of proteins that
pass signals into a cell through cell surface receptor. Wnt signaling was first identified for its role
in carcinogenesis, then for its function in embryonic development. The combined
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phosphoproteomics and siRNA screening study has identified FAM129B as the novel regulator of
Wnt/β-catenin signaling in human melanoma. Silencing of FAM129B inhibits Wnt/β-catenin
target gene expression and apoptotic response to WNT3A. Studies have also mentioned that
FAM129B by itself does not have enzymatic activity or do not have enzymatic domain. However,
it exhibits its cellular effects through protein-protein interaction and around 18 proteins were
identified that interacts with FAM129B including KEAP1.
FAM129B deficiency has also been shown to delay cutaneous wound healing process in
mice (19). This physiological effect was studied by generating gene-targeted FAM129B-mutant
mice in which, the amino terminal coding exon was replaced by lacZ. It was found that
homozygous mutant mice are viable and fertile and that FAM129B is considerably expressed in
most of epidermal keratinocytes of both embryonic and adult mice. However, in the skin of the
FAM129B-deficient mice, wound healing subsequent to skin puncturing was significantly
delayed. Furthermore, overexpression of FAM129B promoted cell motility in an N-terminal
pleckstrin homology domain-dependent manner. This study suggests that FAM129B is necessary
for regulation of cell motility and thereby, contributes to the appropriate wound healing process.
One of the function that FAM129B is known for is the suppression of apoptosis in metastatic
cancer cells. Cancer cells survive by many pathways and many factors are involved in its
development as can be seen in the image by Hanahan and Weinberg. When apoptosis happens,
cells shrinks, disassembling the membrane junctions followed by cell blebbing, DNA
fragmentation and mRNA decay. FAM129B is shown to be present in cytosol in exponentially
growing HeLa cells. However, when cells come in contact and the membrane β-catenin junction
is formed, FAM129B tend to localize at the membrane. Studies done using knockdown FAM129B
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in presence of apoptosis inducing factors such as TNFα/cycloheximide have shown that apoptosis
was 3-4 times faster than in the presence of FAM129B (17).
A very recent study has shown that Epidermal growth factor receptors (EGFR)
phosphorylated FAM129B to promote Ras activation (20). In this paper, the tyrosine residue of
FAM129B (Y593) is shown to be phosphorylated by EGFR which triggers the cascade of Ras
activation leading to uncontrolled cell growth and differentiation. Epidermal growth factor (EGF)
is a growth factor that stimulates cell growth, differentiation and proliferation through EGFR
activation. In normal cells EGF binds to EGFR and this subsequently promotes a cascade of events
leading to Ras and MEK activation. However, in controlled cell growth, the activation and
deactivation of Ras and MEK is maintained by Guanine exchange factors (GEFs) and GTPase
activating protein (GAPs) respectively. In cancer cells, the binding of GAPs is prevented and Ras
continues to be in active state which leads to uncontrolled cell differentiation and proliferation.
It has been shown in this paper that in many cancer cells, EGFR phosphorylated FAM129B at Y593
residue and promotes interaction between FAM129B and H-Ras. This phosphorylation of
FAM129B prevents binding of GAPs and enhances Ras activation.
1.6 FAM129B phosphorylation at its 6 serine residues.
This project mainly focusses on significance of the six serine phosphorylation sites at the
C-terminal end of FAM129B, that is shown to affect localization of FAM129B to the membrane in
confluent cells (16). Also, all six sites showed direct phosphorylation by ERKs. However, the four
sites (Ser628, Ser633, Ser679 and Ser683) showed a strong effect by the direct phosphorylation
as can be seen in the paper Old et.al where the four sites were suppressed more than 2-fold upon
pathway inhibition. Hence, we focused on these four sites to find out which of these sites affects
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FAM129B localization. The study was done by mutating the phosphorylation sites to alanine (A)
thereby preventing any phosphorylation of these sites and see if the function is restored by the
phosphomimic glutamic acid (E). Since Ser628 and Ser633 are close together, our first aim was to
mutate these two together to alanine and phosphomimic glutamic acid. Similarly, Ser679 and
Ser683 was mutated together to Alanine and phosphomimic Aspartic acid. Thus, four mutants
(S628A/S633A, S628E/S633E, S679A/S683A and S679D/S683D) were generated for this study.
The other two serine phosphorylation site (Ser652 and Ser668) were individually mutated to
Alanine and Glutamic acid (S652A, S652E).
As part of this study, preliminary works were also done to see endogenous FAM129B
localization in confluent and non-confluent HeLa cells. Most importantly, it was interesting to see
FAM129B colocalization with N-cadherin, which is a membrane junction protein and is present
only in confluent cells where cell-cell adhesion junctions are formed. Further to this,
immunofluorescence studies was also done on the deletion construct that has all the six
phosphorylation sites deleted. Amino acids from 1-572 was kept intact while all other C-terminal
regions were deleted which includes the six serine phosphorylation sites as well. Expression of
these regions also gave an important information on FAM129B localization in confluent HeLa
cells.
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CHAPTER 2 MATERIALS and METHODS
2.1 Polymerase Chain Reaction Site Directed Mutagenesis
2.1.1 Primer Design
Mutants for the phosphorylation studies were made using New England Biolabs (NEB) site
directed mutagenesis kit. Wild type FAM129B cloned in pEGFP vector with Kanamycin resistant
tag was used as a template for the PCR reactions. The whole plasmid is approximately 8000bp.
The PCR Site Directed Mutagenesis was carried out on the whole plasmid. Proper primer design
guidelines were used from IDT oligo analyzer tool from Integrated DNA Technologies. Primers for
the PCR were generated using IDT oligo analyzer and the forward primer contained both the
mutants. Both forward and reverse primers are phosphorylated at the 5-prime end for effective
ligation of the linear strand formed in PCR cycle. The 5-prime phosphorylated forward and
reverse primers were supplied by Thermo Fishers.
Mutants

Forward Primer

Reverse Primer

S628_633A

5’(Phos)ctgag GCTccaccacctgcgGCTcc…

5’(Phos)ggctagcctcaaagggcagccccacc

S628_633E

5’(Phos)ctgagGAAccaccacctgcgGAAccgg 5’(Phos)ggctagcctcaaagggcagccccacc

S679_683A

5’(Phos) cctccGCTccgcctgccGCTc

5’(Phos)cctcgggggcggccttaggct

S679_683E

5’(Phos)gcctccGAAccgcctgccGAAcc

5’(Phos)ctcgggggcggccttaggct

S652A

5’(Phos)gcctgagGCTcccccacca

5’(Phos)cgcagaccttgggccagca

S652E

5’(Phos)gcctgagGAAcccccacca

5’(Phos)cgcagaccttgggccagca

Table 2.1: PCR forward and reverse primers for all the mutants. The codons highlighted in bold
shows the mutation sites with the codon for serine changed to respective alanine and glutamic
acid codons. The reverse primers do not contain the mutation. Both the forward and reverse
primers are phosphorylated at 5’ end and is provided in a purified form using desalt technique.
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2.1.2 PCR Site Directed Mutagenesis
The recombinant FAM129B expression plasmid cloned in pEGFP vector was previously
made by Dr. Song Chen in our lab (17). FAM129B was also cloned into pEGFP-C3 vector to
generate a fluorescent fusion protein. The whole plasmid is around 8000bp with the GFP tag at
the amino end. To generate mutants, whole plasmid site directed mutagenesis was carried out
with both reverse and forward primers. The forward primers carried the mutations to be
incorporated. Around 30-50 ng of GFP-FAM129B was used for the reaction and mixed with Q5
reaction buffer (NEB #B9027S), dNTPS (NEB #N0447S), primers, Q5 Polymerase (NEB #M0491S)
and GC enhancer (NEB #B9028A) as per manufacturer’s protocol. It was made sure that
polymerase was added after all other components were added except GC enhancer which was
added at the last step. The final reaction volume is brought to 50µl using ultra-pure nuclease free
water. PCR mix was placed in Eppendorf Master Cycler Gradient Thermal Cycler and the reaction
was carried out for 18-22 cycles. The PCR product was then run through agarose gel to visualize
the bands corresponding to FAM129B. The protocol is summarized in the following table.
Component

50µl reaction

Final Concentration

Q5 Reaction Buffer

10 µl

1X

10 mM dNTPs

1 µl

400 µM

10 µM Forward Primer

2.5 µl

0.5 µM

10 µM Reverse Primer

2.5 µl

0.5 µM

Template DNA

Variable

30-50 ng

Q5 High-Fidelity DNA Polymerase

1 µl

0.04 U/µl

5X Q5 GC Enhancer

10 µl

1X

Nuclease-Free Water

Up to 50 µl
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Table 2.2: Optimized PCR Reaction mix for Site Directed Mutagenesis. All mixing was done on
ice in a PCR tube. The GC enhancer is optional, however since the plasmid has high GC content
(60-70%), it was found to be effective.
Thermocycler conditions
Step

Temperature

Time

Initial Denaturation

98°C

2 minutes

18-22 Cycles

98°C

30 seconds

*Ta

1 minute

72°C

30 seconds/Kb

Final Extension

72°C

8 minutes

Hold

4°C

*Annealing temperature is obtained from primer design software. Usually temperature 1-2°C
below that the mentioned is used for the thermocycler.
Table 2.3: Thermocycler conditions for FAM129B Site Directed Mutagenesis. Initial
denaturation temperature can vary depending on the amount of template used. For low
template concentration, initial denaturation temperature should be from 1 to 1 1/2 minutes.

2.1.3 Gel Electrophoresis
The Easy Cast DNA electrophoresis apparatus from Owl Separation Systems was used for
electrophoresis of DNA samples. 0.8% agarose gel was made by dissolving 0.8g UltraPure Agarose
(Invitrogen) in 100 ml 1XTAE buffer (40mM Tris base, 0.1% acetic acid, 1mM EDTA, pH8.0) and
heated for 1-2 min in a microwave until boiling. The boiled agarose was cooled down to about
50°C and 10µl of SYBR Safe DNA gel stain (S33102- 24 Invitrogen) was added. The agarose solution
was then poured into a gel casting apparatus and a 1.5mm 10-well comb was inserted for
formation of the loading well. The gel was then allowed to solidify at room temperature and
placed in the tank filled with TAE buffer. Samples were prepared by mixing the DNA to loading
dye (Invitrogen #R0611) at a ratio 1:5. The samples were loaded in the gel, along with a DNA

13

standard, 1Kb (Invitrogen #15615-016). The agarose gel was run at 90-100V for 45 minutes, or
until the bromophenol blue dye ran approximately ¾ of the length of the gel. The DNA fragments
were then viewed and photographed using a UV transilluminator.
2.1.4 PCR Purification
The PCR reaction generates linear plasmids which needs to be ligated to form a circular
plasmid for efficient transformation. Before proceeding to the ligation reaction, the PCR product
was cleaned up using Qiagen PCR Purification Kit (Cat# 28104). The purification was carried out
as per the manufacturer’s protocol and 30µl elution buffer was used to elute the DNA in more
concentrated form. PCR purification was carried out using PureLink Gel Extraction Kit (Invitrogen
# K2100-12) and PureLink PCR Purification Kit (Invitrogen # K3100-01). However, a better yield
and purity of the purification was obtained from QIAquick PCR Purification Kit (Qiagen).
2.1.5 Ligation
After PCR was carried out at the specified conditions, the linear mutated strands were
ligated using Blunt/TA Ligase Master Mix (NEB #M0367S). The PCR reaction generated blunt end
linear strands, hence this ligase was much specific and efficient. Around 50 ng of purified PCR
product was treated with ligase master mix. Before starting the reaction, the components in the
master mix tube were mixed by finger-flicking and transferred to the sample to be ligated. The
reaction mix was made by pipetting up and down 7 times slowly. The volume of master mix used
was approximately 50% of the total reaction volume. The reaction was carried out for 15-20
minutes at room temperature (25°C). After this the reaction, the mixture was kept on ice for 3
minutes to inactivate the ligase.
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2.2 Gene Sequencing and Analysis
The plasmids were sent for sequencing to Genscript and Genewiz sequencing service. The
samples were premixed with the sequencing primer (5’ CGAGGAAGTACAGCAACA 3’) as per the
companies’ protocol. The sequencing primer was chosen in such a way that it is 100bp upstream
of the mutation sites. Also, GC content of the sequencing primer was limited to 55% and its
annealing temperature in the range of 55 - 60°C. The sequencing results were analyzed using
NCBI blast or ClustalW for pairwise alignment. The trace files, chromatogram that show peaks for
respective nucleotides, were also analyzed in BioEdit Sequence Alignment Editor.
2.3 Transformation
One Shot Top10 competent cells were provided by Invitrogen (C4040-10). Cells were
thawed on ice and around 20ng of ligated plasmids were added to 10µl of Top10 cells. The
mixture was incubated for 30 minutes on ice and followed by heat shock for 30 seconds at 42°C
and then placed on ice for 3 minutes. The cells were incubated in recovery media or SOC media
for 1 hour at 37°C with shaking. The outgrowth is then spread onto kanamycin resistant agar
plates and incubated overnight at 37°C. The colonies formed on the plates were incubated
overnight at 37°C with shaking at 218 rpm in 5ml LB media to extract plasmid. These were sent
for sequencing to confirm the mutations.
2.4 Top10 Competent cells
Top10 competent cells were also made in lab using the lab protocol. TSS method was used
for transformation purpose and for long-term storage of Top10 cells. Before starting, the work
bench, gloves and all pipettes to be used were sterilized. This is done to prevent any
contamination because, in the whole process of making Top10 cells, no antibiotics were used or
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added to cell culture. LB agar plates with no antibiotics were streaked with Top10 and incubated
overnight at 37°C. A single colony was picked from this and cultured in 5ml LB by overnight
incubation at 37°C with shaking at 280 rpm. 1 ml of this overnight culture was then inoculated in
100ml autoclaved LB in large flask with no antibiotics. This is grown at 37°C, 280 rpm till the
optical density @600 nm reaches 0.3-0.4. Once the OD reached the required value, the flask was
kept on ice for 15 minutes and then centrifuged in an autoclaved falcon tube at 3000rpm for 20
minutes at 4°C. After this it was kept on ice and all subsequent steps were carried on ice. After
discarding the supernatant, the cell pellet was re-suspended in 10ml ice-cold TSS buffer and
mixed thoroughly by pipetting the suspension up and down. This was then spin down at 3000
rpm for 20 minutes at 4°C. The supernatant was discarded and the cell pellet was re-suspended
in 0.9 ml ice-cold TSS and 0.1 ml ice cold 80% glycerol. The cells were then aliquoted into precooled 1.7ml centrifuge tubes on ice and stored at -70°C.
2.5 Plasmid Purification
For plasmid extraction, PureLink Quick Plasmid Miniprep kit form Invitrogen (Invitrogen
#K210010) was used. Around 3-5 ml culture was centrifuged at 4000 rpm for 6 minutes. The
supernatant was discarded and the cell pellet was suspended using resuspension buffer (50 mM
Tris-HCl, pH 8.0; 10 mM EDTA 20 mg/ml RNase). This was treated with lysis buffer (200 mM NaOh,
1% w/v SDS) and incubated for 5 minutes. After this, precipitation buffer was added and the
solution is centrifuged for 10 minutes at 12000 rpm. The supernatant is loaded in the column and
centrifuged at 12000 rpm for 1 minute. The column was eluted with wash buffer and centrifuged
twice to remove any addition wash buffer. In the final step, plasmid is eluted using elution buffer
under centrifugation at 12000 rpm for 2 minutes. The concentration of DNA was measured using
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NanoDrop. For transfection and immunofluorescence studies, plasmid purification was carried
out using PureLink HiPure Plasmid Miniprep Kit (Invitrogen #K210002). Plasmids of high purity
and high concentration is obtained from this kit which increase the efficiency of transfection in
cells.
2.6 Cell Culture (HeLa Cells)
HeLa cells are maintained in Dulbecco’s Modified Eagle Media (DMEM) with 10% Fetal
Bovine Serum (FBS). To avoid any contamination at initial thawing, 1% antibiotics are also added
to DMEM. Cells are passaged when the confluency reaches around 80%. For cell splitting, all
media is aspirated and treated with 3.5 ml trypsin. The flask is then incubated for 2-3 minutes
until all the cells settle out of suspension. To this 5 ml DMEM with 10% FBS is added to inactivate
trypsin by the serum. The whole suspension is then centrifuged at 2500 rpm for 5 minutes at 4°C.
The media is removed and the cells are suspended in 2 ml freezing media (DMEM + 5% DMSO).
These are then transferred to cryogenic vials and kept at -80 for 24 hours before storing in liquid
nitrogen. For thawing, the frozen vial is taken from liquid nitrogen and immediately warmed by
rapidly shaking in water bath at 37°C. Once the cells are thawed, it is transferred to T-75 flask
with 5-7 ml media with antibiotic.
2.7 Transfection
Transfection was carried out using Lipofectamine 2000 reagent from Invitrogen (Cat #
11668027). HeLa cells were plated in 6-well plates a day before transfection. On the day of
transfection, the cells reached a confluency of 60 –80%. DNA-Lipofectamine transfection complex
were made at a ratio of 1:2 in Opti-MEM Reduced Serum Media and incubated for 15 minutes
before adding to HeLa cells in the culture. The complex was added directly to cells in culture
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medium with serum and no antibiotics. After 4 hours, the media was changed to fresh DMEM
media with 10% FBS.
2.8 Immunofluorescence
Cells were grown on glass coverslips to 80% confluence and fixed in 1% paraformaldehyde
for 15 min and permeabilized in 0.2% triton X-100 for another 15 min. After three 5 min washes
in phosphate buffered saline (PBS), the coverslips were blocked in 1% BSA for 1 hour and 30 min.
Coverslips were then incubated with primary antibodies, Rabbit anti-GFP polyclonal antibody
(Genscript #A01388-40) for 2 hours, washed 3× 5 min with PBS, and incubated in secondary
antibody goat anti-rabbit IgG antibody, alexa fluor 488 (Invitrogen #A11034) for 1 hour. For study
of endogenous FAM129B colocalization with N-cadherin, imaging was done using primary rabbit
FAM129B antibody (Cell Signaling #5122S) and mouse N-cadherin antibody (Cell Signaling
#14215) were used. However, the secondary antibody was goat anti-rabbit IgG alexa fluor 488
for endogenous FAM129B and goat anti-mouse IgG Alexa Fluor 594 (Invitrogen # A-11032) for Ncadherin. Coverslips were washed 3× 5 min in PBS and mounted in ProLong Gold antifade reagent
with DAPI (Invitrogen #P36931). The slides were dried overnight by properly covering with
aluminum foil and placing in dark area. Images were collected using 40X oil immersion lens under
Nikon Eclipse E800.
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CHAPTER 3 RESULTS
3.1 PCR Cloning to generate FAM129B mutants
A previous study has shown that the six serine phosphorylation sites of FAM129B plays an
important role in its localization to membrane the junctions (16). The sites Ser628 and Ser633
are located close to each other and hence both were mutated to Alanine together. To make the
phosphomimic, these two sites were mutated to glutamic acid using the PCR site directed
mutagenesis technique. Sites Ser679 and Ser683 were also mutated together to Alanine and
Aspartic acid residues. When following the manufacturer’s protocol, a faint or no band specific
for FAM129B was observed (Fig.3.1A). A few parameters were then changed to see how they
affect the PCR efficiency. When tried with different initial denaturation time, it was seen that
long denaturation time tend to cause the bands to smear in gel, which may be due to multiple
PCR products (Fig.3.1B). An optimal time of 1-2 minutes for initial denaturation was found to be
effective and the gel showed much less smearing (Fig.3.1C). The protocol was optimized by
employing different conditions and changing numerous parameters to generate a good PCR
product. This is seen as a strong band in gel electrophoresis that corresponds to the size of
FAM129B which is around 8Kb (Fig3.1D). The final mutant plasmids purified from plasmid
miniprep kit shows 8Kb FAM129B in the gel (fig 3.1E).
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8 Kb
8 Kb

8 Kb

8 Kb

Fig 3.1. FAM129B Gel images of PCR product.
(A). No band corresponding to FAM129B was seen when used manufacturer’s protocol and ran
for 30 cycles.
(B). Smear showing multiple band formation due to high denaturation temperatue. Initial
denaturation was given for a longer time of 5 minutes by keeping other conditions constant.
(C). Faint band with low concentration. Shows successful PCR, however, product concentration
was too low (10-12 ng) for further ligation process.
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(D). Optimized PCR condition shows strong band around 8Kb. By changing template and primer
concentration and optimizing thermocycler conditions, a strong band for PCR product was seen
and a concentration of 130ng was obtained as measured from NanoDrop.
(E). Gel image of FAM129B plasmids (wild type and mutants) extracted from Top10 culture using
plasmid miniprep kit. Band F1 and F2 corresponds to Wild type FAM129B and F3- F8
corresponds to the six mutants of FAM129B. The gel shows two band, one corresponding to 8Kb
and other lower supercoiled band which is the native confirmation of DNA.

3.2 Confirmation of mutants using Sanger Sequencing (Genewiz and Genscript)
After successfully generating PCR products, it was ligated using blunt/TA ligase kit form NEB
and then transformed to TOP10 E.coli cells. Very few colonies were formed and different colonies
were cultured overnight in LB media. The plasmids were extracted and send for sequencing. The
sequencing results were analyzed using NCBI blast tool. The mutants were compared with wild
type FAM129B and as can be seen the sequence is identical except those sites where the base
changes have been introduced. As can be seen in the sequence alignment, serine codons TCG
and TCA were mutated to alanine codons GCT and GCA respectively (Fig 3.2A). This confirms
mutation of serine to alanine at position 679 and 683 respectively. The Ser679 codon TCG was
mutated to aspartic acid codon GAT and the Ser683 codon TCA was mutated to aspartic acid
codon GAC (Fig 3.2B). This confirms the aspartic acid phosphomimic of Ser679Asp and Ser683Asp.
Mutants of Ser652 were also analyzed by sequencing. The serine codon AGC is mutated to alanine
codon GCT using site directed mutagenesis technique (Fig 3.2C). To generate S652E, the serine
codon AGC is mutated to glutamic acid codon GAA. Confirmation of the mutations Ser652Ala and
Ser652Glu were shown in Fig 3.2D.
A. TCG/TCA

GCT/GCA

Ser678Ala and Ser683Ala
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B. TCG/TCA

C. AGC

GAT/GAC

GCT

Ser678Asp and Ser683Asp

Ser652Ala
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D. AGC

GAA

Ser652Glu

Fig. 3.2. Confirmation of mutations through Genewiz sequencing. The sequencing results were
compared with the wild type FAM129B using multiple sequence alignment tool
https://blast.ncbi.nlm.nih.gov
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(A) Blast sequence alignment shows the serine codons (TCG/TCA) of wild type FAM129B is
mutated to alanine codon (GCT/GCA). The alanine mutant act as a non-phosphorylation site and
prevents FAM129B phosphorylation at position 679 and 683.
(B) Sequence alignment shows mutation at 679 and 683 where serine is codon (TCG/TCA) is
converter to the phosphomimic aspartic acid (GAT/GAC). This keeps these two sites always in
phosphorylated state.
(C) The serine codon (AGC) at position 652 is mutated to alanine (GCT) that preventing
phosphorylation of this site.
(D) Serine codon (AGC) at 652 is mutated to glutamic acid (GAA) which mimics phosphorylation.

3.3 Immunofluorescence studies to check the effect of mutants on FAM129B localization.
3.3.1 GFP-FAM129B membrane colocalization with N-cadherin.
Previous studies have shown that FAM129B is overexpressed in cancer cells and it
localizes to membrane in confluent cells (17). To study this, HeLa cell lines were chosen to see
the localization of endogenous FAM129B using immunofluorescence technique. Cells were also
transfected with GFP-FAM129B (wild type) and checked for localization. Localization of GFPFAM129B was compared with the membrane protein N-cadherin. Cadherin is a transmembrane
protein that plays an important role in cell adhesion, forming adherent junctions to bind cells
with tissues together. There are different types of cadherin. N-cadherin is found in HeLa cells,
whereas these are absent in A549 lung cancer cells. When membrane junctions are not formed,
N-cadherin is not seen at the membrane of HeLa cells. However, in confluent HeLa cells, Ncadherin is seen in the membrane junctions. As can be seen in Fig 3.3, endogenous FAM129B
(green) colocalizes with N-cadherin (red) at the membrane. In cells that are not in contact with
each other FAM129B is not at the membrane as there is no membrane junction formed as can
be seen by the absence of N-cadherin. Experiments were also done by transfecting GFP-FAM129B
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and observe its localization in confluent and non-confluent HeLa cells (Fig. 3.4). GFP-FAM129B
was treated with Rabbit anti-GFP polyclonal antibody (Genscript #A01388-40) that specifically
shows signal for transfected FAM129B.

Fig 3.3 Endogenous FAM129B localization in confluent HeLa cells. Cells were plated on
coverslips at different confluency. The cells were treated with primary antibody FAM129B rabbit
antibody (Cell signaling #5122S) and N-cadherin mouse mAb (Cell signaling #14215S) for 2 hours.
The secondary antibody for FAM129B (green) is goat anti-rabbit IgG Alexa Fluor 488 (Invitrogen
#A11034) and for N-cadherin (red) is goat anti-mouse IgG Alexa Fluor 594 (Invitrogen #A11032)
for 1 hour. The immunofluorescence protocol is as followed in materials and methods.
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Fig 3.4 GFP-FAM129B transfected in HeLa cells showing membrane localization in confluent
and non-confluent cells. Transfection was carried out with lipofectamine at a ratio of 1:2 DNA
to lipofectamine. Transfected cells were treated with rabbit anti-GFP primary antibody
(Genscript #A01388-40) for 2 hours and incubated in secondary antibody goat anti-rabbit IgG
antibody, alexa fluor 488 (Invitrogen #A11034) for 1 hour.
(A) Diagram showing positions of six serine phosphorylation sites of wild type GFP-FAM129B.
(B) Immunofluorescence image of wild type FAM129B sowing localization to membrane in
confluent HeLa cells. Whereas, cells that are not in contact, FAM129B is shown to be dispersed
in cytoplasm.

3.3.2 Membrane localization studies using C-terminal deletion construct.
C-terminal deleted region that has all the six serine phosphorylation sites removed of
FAM129B was made by a previous student, Dr. Song Chen, in our lab. This deletion construct with
GFP tag at the amino end was transfected in HeLa cells and protein expression at the membrane
was studied after 48 hours through immunofluorescence using rabbit anti-GFP primary antibody
and goat anti-rabbit IgG secondary antibody. Amazingly the immunofluorescence images show
that FAM129B does not localize to membrane in confluent HeLa cell. They are mostly distributed
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in cytoplasm just like the non-confluent cells (Fig. 3.5). This suggests that the six serine
phosphorylation sites play an important role in FAM129B localization in confluent HeLa cells.

Fig 3.5 FAM129B C-terminal deletion construct lacks all phosphorylation sites and is not
localized to membrane in confluent HeLa cells.

3.3.3 Membrane localization studies with FAM129B mutant, S628A and S633A and S628E
and S633E.
In this experiment, two of the serine phosphorylation sites were mutated to alanine and
glutamic acid and its localization was studied. Ser628 and Ser633 were mutated together to
alanine to study its effect on FAM129B membrane localization. The immunofluorescence study
using anti GFP antibodies shows that FAM129B Ser628Ala/Ser633Ala mutant localizes to
membrane in confluent HeLa cells (Fig. 3.6). Since serine phosphorylation is mediated by EGF,
these cells were treated with EGF for 30 minutes in serum free media and checked for membrane
localization. It is seen that FAM129B Ser628Ala/Ser633Ala localizes to membrane in a similar
fashion as without EGF or cells grown in 10%FBS DMEM. The phosphomimics
Ser628Glu/Ser633Glu were studied in similar manner and its seen that the phosphomimics
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localize to membrane in confluent HeLa cells (Fig 3.6). This suggests that phosphorylation and
de-phosphorylation of these two sites does not play an important role in FAM129B localization.

Fig 3.6. Localization of FAM129B mutant S628E and S633E.
(A) Diagram showing location of the six serine phosphorylation sites and the position of mutants.
Here, the serine phosphorylation sites were mutated to alanine (S628A and S633A) and glutamic
acid (S628E and S633E).
(B) Immunofluorescence image of FAM129B mutant showing localization to the membrane. The
alanine mutant and the phosphomimic glutamic acid, both shows membrane localization
suggesting that dephosphorylation and phosphorylation of serine at position 628 and 633 has no
effect on FAM129B localization in confluent HeLa cells.

28

3.3.4 Membrane localization studies with FAM129B mutant, S679/683A and S679/683D.
The serine phosphorylation sites that were close to the C-terminal region of FAM129B
were mutated to alanine for analyzing FAM129B membrane localization. As seen, FAM129B
Ser679Ala and Ser683Ala did not localize to membrane in confluent HeLa cells. Since serine
phosphorylation is mediated by EGF, FAM129B Ser679Ala/Ser683Ala transfected cells were
treated with EGF for 30 minutes in serum free media and checked for membrane localization. It
is seen that FAM129B Ser679Ala/Ser683Ala again did not localize to membrane in a similar
fashion as without EGF (Fig 3.7B). The phosphomimics Ser679Glu/Ser683Glu were studied in
similar manner and showed that the phosphomimics localize to membrane in confluent HeLa
cells. This suggests that eliminating phosphorylation of S679A/S683A prevents its localization to
membrane in confluent cells and the phosphorylation of these two sites play an important role
in FAM129B localization (Fig. 3.7B).
Since the alanine mutant of Ser679 and Ser683 together prevented FAM129B localization
to membrane in confluent HeLa cells, it was interesting to know if one had any effect on the
localization. Hence, a single mutation was done in which only Ser683 was mutated to alanine and
checked by immunofluorescence microscopy, whereas, all other sites were serine. This mutant
was previous made in our lab by Dr. Song Chen. It was seen that a single mutation to alanine did
not show the same effect as the double mutant. FAM129B would still localize to membrane in
confluent cells (Fig. 3.7D). The phosphomimic Ser683Asp also localizes to membrane like
Ser683Ala (Fig.3.7D). This suggests that phosphorylation and dephosphorylation of Ser683 alone
does not play an important role in FAM129B localization to membrane in confluent HeLa cells.
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Fig 3.7 Effect of FAM129B phosphorylation and dephosphorylation at positions S679 and S683.
(A) Diagram showing position of serine mutant. Serine at position 679 and 683 were mutated to
alanine so that it is prevented from phosphorylation at these two sites and to phosphomimic
aspartic acid that keeps these two positions always phosphorylated.
(B) Immunofluorescence image shows that dephosphorylation of FAM129 at positions Ser679
and Ser683 prevents its localization to membrane. However, the phosphomimic mutant brings it
to the membrane junction in confluent HeLa cells.
(C) Diagram showing position of mutant Ser683Ala and Ser683Asp.
(D) Single mutation at 683 position to alanine showed no effect on FAM129B localization. Both
the alanine and phosphomimic mutant shows FAM129B localization to membrane in confluent
HeLa cells.

3.3.5 Membrane localization studies with FAM129B mutant, S652A and S652E.
Ser652 and Ser668 are also serine phosphorylation sites of FAM129B. They are located
very far apart from each other in contrast to the two pairs. Also, these sites are not strongly
phosphorylated by MAP kinase when compared to the other four sites (16). The phosphorylation
sites Ser652 was chosen to see if it plays any role in membrane localization of FAM129B. Ser652
was mutated to alanine, keeping all other phosphorylation sites intact. The alanine mutant
prevents any phosphorylation at this position due to the absence of serine. The mutant is
analyzed for membrane localization by immunofluorescence microscopy using antibody directed
against GFP. As seen in the fig.3.8, FAM129B localizes to membrane in confluent HeLa cells. This
shows that Ser652 does not play any role in FAM129B membrane localization. The phosphomimic
mutant Ser652Glu showed similar results suggesting that phosphorylation and dephosphorylation of FAM129B at Ser652 position does not affect its membrane localization (Fig.
3.8).
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Fig 3.8. FAM129B localization studies on the mutant Ser652A/E.
(A) Diagram showing position of mutants Ser652Ala and Ser652Glu.
(B) Phosphorylation and dephosphorylation of FAM129B at position Ser652 has no effect on
FAM129B localization to membrane. The alanine mutant S652A and the phosphomimic S652E
both localizes to membrane in confluent HeLa cells.
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CHAPTER 4 DISCUSSION
The protein encoded by FAM129B gene, has not been widely studied. Also, the protein
structure is unknown. Its purpose and function is only basically understood. However, it is known
that FAM129B interacts with protein receptor EGFR and promotes a cascade of events that leads
to transformation of normal cell to cancer cell (20). This makes it important to study FAM129B at
the molecular level and the effect of the mutation of key residues. Future studies on FAM129B
might help us understand and know if it can be used as a potential drug targeting agent to treat
cancer cells. In this project, FAM129B was studied at the gene level by phosphorylation and
mutations on the six serine residues and its effect on cells were observed by the localization of
protein coded by this gene. It is well known that FAM129B is expressed highly in many forms of
cancer and in confluent cells, it colocalizes at the membrane with β-catenin membrane junction
protein (17). However, study done by Old et.al and group has seen a change in membrane
localization behavior of FAM129B when all six serine phosphorylation sites were mutated. Hence,
in this study the phosphorylation sites were tested pairwise and individually to point out the
specific serine residue that changes the behavior of FAM129B pertaining to membrane
localization.
Previous studies on FAM129B and repeated experiments have shown that FAM129B
localizes to membrane in confluent HeLa cells. Immunofluorescence studies on endogenous
FAM129B using FAM129B antibodies have frequently shown that FAM129B co-localizes with Ncadherin in confluent HeLa cells (Fig. 3.3). Also, these localizations of FAM129B has been shown
to be affected by the six serine phosphorylation sites. Hence, when C-terminal deleted FAM129B,
with all the six serine phosphorylation sites removed, is transfected in HeLa cells, the
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immunofluorescence image shows more dispersed FAM129B in cytoplasm rather than the
localized endogenous FAM129B in confluent HeLa cells (Fig. 3.4). This suggests that the six serine
phosphorylation sites play an important role in FAM129B localization in confluent HeLa cells.
GFP-FAM129B wild type localization was studied in HeLa cells. They were transfected and
the membrane localization was studied by immunofluorescence imagining after 48 hours of
transfection (Fig. 3.5). It is seen that they localize to membrane in confluent HeLa cells. However,
in exponential cells when cells are not in contact with each other, FAM129B is mostly dispersed
in cytoplasm. Unless the cells are in physical contact the adherens junctions are not formed. This
is seen by analyzing the important membrane junction protein N-cadherin that can be seen in
the cell-cell adhesion junction. However, since junction are not formed in exponential cells, Ncadherin is absent and cannot be seen by immunofluorescence imaging. This behavior is similar
to FAM129B localization. This suggest that FAM129B localizes to membrane only in confluent
cells when the adherens junctions are formed. Since cell-cell adherens junctions are not formed
in exponential cells, FAM129B is mostly dispersed in cytoplasm (Fig. 3.4).
Four of the six MAPK phosphorylation sites are located in the sequence in pairs in which
the targeted serine residues are separated by only 4 or 5 amino acid residues; in one pair Ser628
and Ser633 and in the other Ser679 and Ser683. Both serine residues in each pair were mutated
simultaneously. The other two sites, 652 and 665 were spaced further apart and located
between the two pairs. S652 was studied to see its effect in localization. The pair S628A and
S633A, that cannot be phosphorylated were still localized to membrane similar to the wild type
FAM129B. The phosphomimic of these two sites S628E and S633E also showed membrane
localization like the wild type FAM129B in confluent HeLa cells. Thus, phosphorylation and de-
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phosphorylation of sites S628 and S633 does not play any role in FAM129B membrane
localization (Fig. 3.6 B).
The pair S679/S683 were mutated together to alanine (S679A/S683A) and examined by
immunofluorescence microscopy. Surprisingly, when these two sites were mutated to alanine
and thus could not be phosphorylated, FAM129B does not localize to the membrane in either
confluent or exponentially growing cells. They are mostly seen dispersed in cytoplasm. This
suggests that blocking phosphorylation of these two sites prevented localization of FAM129B to
membrane in confluent HeLa cells. The phosphomimic of these two sites however, showed
membrane localization when cells are in contact with each other. This specifically suggest that
dephosphorylation of S679 and S683 prevents FAM129B localization and the phosphorylation at
S679 and S683 takes its to the membrane in confluent cells (Fig. 3.7 B). Further analysis was done
for these two sites by studying S683 alone. Hence S683A and S683D mutants were transfected in
HeLa cells and after immunofluorescence study it was seen that both the mutants behave similar
to the wild type by localizing to membrane in confluent HeLa cells (Fig 3.7 D). This suggest that
either the pair needs to be phosphorylated or just S679 needs to be phosphorylated to prevent
FAM129B localization to membrane. These two sites thus provide us with an important
information on the invasiveness of cancer cells since FAM129B localization has been shown to
affect cancer cell invasion and thus metastasis.
The other two sites S652 and S668 are weakly phosphorylated by MAP kinase/ERK
pathway. This is shown by studies done by Old et.al when they inhibited MEK kinase, the kinase
that activates MAP kinase and found that the phosphorylation of all six serine residue was
diminished. However, the activity of four sites S628, S633, S679 and S683 were suppressed twice
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as compared to S652 and S668 phosphorylation sites which were very less dephosphorylated or
their phosphorylation is unaffected. The site S652 was mutated to alanine and studied for
FAM129B localization. It showed localization like wild type FAM129B and hence do not play any
role in FAM129B membrane localization. The phosphomimic S652E also localized to membrane
in confluent HeLa cells suggesting that phosphorylation and de-phosphorylation of Ser652 does
not play any important role in FAM129B colocalization with N-cadherin (Fig. 3.8 B).

FAM129B
Wild Type
Deletion Mutant
S628A and S633A
S628E and S633E
S679A and S683A
S679D and S683D
S683A
S683D
S652A
S652E

No Cell Contact
Cytoplasm
Cytoplasm
Cytoplasm
Cytoplasm
Cytoplasm
Cytoplasm
Cytoplasm
Cytoplasm
Cytoplasm
Cytoplasm

Cell Contact
Membrane
Cytoplasm
Membrane
Membrane
Cytoplasm
Membrane
Membrane
Membrane
Membrane
Membrane

Table 4. Summary of FAM129B Mutant Intracellular Location. Table shows the mutants and
their corresponding effect on FAM129B localization in confluent (cell contact) and nonconfluent (no cell contact) HeLa cells. As seen, the deletion construct that has all the six serine
phosphorylation sites deleted and the mutant pair S679A/S683A, prevents FAM129B
localization to membrane in confluent HeLa cells.

Metastasis and invasion is the leading cause of high mortality rate of patients with cancer.
The main reason for these characteristics of cancer cell is the disruption of adherens junction
which consists of protein complexes that keep the cell to cell contact intact in epithelial and
endothelial tissues. During metastasis, the adherens junctions are disrupted leading to
detachment of cancer cell and its spreading to another part of the body. FAM129B is known to
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be associated with cancer cell invasion in melanoma cells (16). Invasion studies done by Old et.al.
shows that knockdown of endogenous FAM129B in melanoma cells blocked its invasion into a
collagen matrix. Also, invasion was prevented when all the six phosphorylation sites were not
phosphorylated. This signifies that FAM129B plays an important role in melanoma cell invasion
and phosphorylation of the six serine residue play a key role in metastasis and invasion of cancer
cells. Further research on the six serine phosphorylation residues will shed some light on how the
phosphorylation affects the metastasis and invasion, thus making FAM129B as a potential drug
target for cancer therapy.
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Phosphorylation and de-phosphorylation of many proteins is a key regulator of cellular life. It
maintains cellular activity through an array of signaling pathways like cell division, proliferation
and growth. However, Overexpression or mutations by the constitutive activation of
phosphorylation machinery disrupt the balance in the cell, driving the inappropriate activation
or deactivation of the cellular processes it controls. FAM129B is a protein whose activity is partly
maintained by phosphorylation and dephosphorylation at the six serine residues at the Cterminal. FAM129B is expressed highly in many forms of cancer and its main function is to
suppress apoptosis and enhances cancer cell invasion. In this project, FAM129B phosphorylation
studies are done to see how the mutation at the serine residues affects its localization to
membrane in confluent HeLa cells. We demonstrated that endogenous FAM129B colocalizes
with N-cadherin at the adherens junction in confluent HeLa cells. However, deletion of the six
serine residues phosphorylated by MEK, prevented its localization to membrane in confluent
cells. It is seen that out of the six serine residues, the two residues Ser679 and Ser683 plays an
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important role in FAM129B localization. The alanine mutant of Ser679Ala and Ser683Ala
prevented FAM129B localization to membrane in confluent HeLa cells and the activity is restored
by the phosphomimic glutamic acid mutant Ser679Asp and Ser683Asp shows membrane
localization at the cell-cell adherens junction. Thus, blocking phosphorylation of Ser679 and
Ser683 prevented FAM129B localization to membrane and its phosphorylation takes the
FAM129B to the membrane in confluent cells. It is also studied that the phosphorylation and
dephosphorylation of the other serine phosphorylation sites, Ser628, Ser633 and Ser652 has no
effect on FAM129B membrane localization in confluent HeLa cell.

